CIK 0001683553 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 0 | 10.1 M | 0 | |
| Net income (USD) | -47.9 M | -46.2 M | -42.3 M | |
| Diluted EPS (USD/shares) | -50.83 | -1.24 | -1.96 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-08-14 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-12 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-12 | 8-K | 8-K items 2.02,9.01 | 2026-08-12 |
| 2026-08-04 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-30 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-29 | 4 | 4 | 2026-07-27 |
| 2026-07-29 | 3 | 3 | 2026-07-27 |
| 2026-07-27 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-27 | 8-K | 8-K items 5.02 | 2026-07-27 |
| 2026-07-09 | 4 | 4 | 2026-06-30 |
| 2026-05-26 | 4 | 4 | 2026-05-21 |
| 2026-05-26 | 4 | 4 | 2026-05-21 |
| 2026-05-26 | 4 | 4 | 2026-05-21 |
| 2026-05-26 | 4 | 4 | 2026-05-21 |
| 2026-05-26 | 4 | 4 | 2026-05-21 |
| 2026-05-26 | 8-K | 8-K items 5.07,9.01 | 2026-05-21 |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-13 | S-8 | S-8 | |
| 2026-05-13 | 10-Q | 10-Q | 2026-03-31 |
Forms on file (last 1,000): 4 111, 8-K 63, 3 24, 10-Q 18, SC 13G/A 16, SCHEDULE 13G/A 14, SCHEDULE 13G 13, SC 13D/A 13. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=SPRB (0.002 USD), /gw/filings/filings?ticker=SPRB&form=8-K, /gw/filings/facts?ticker=SPRB&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange